The Effect of Erector Spinae Plane Block (ESPB) on Pediatric Pain Management Following Posterior Spinal Fusion (PSF) Surgery

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07561827
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Adolescent Idiopathic Scoliosis
  • Adolescent Idiopathic Scoliosis (AIS)
  • Neuromuscular Scoliosis

Eligibility Criteria

Sex
ALL
Age
10 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Ropivacaine Hydrocloride — DRUG
    This drug is approved as a local anesthetic.

Study Details

This study is being done to better understand the efficacy of an erector spinae plane block (ESPB) in pain management for children with Adolescent Idiopathic Scoliosis or Neuromuscular Scoliosis undergoing Posterior Spinal Fusion surgery. The study team is trying to find out if receiving the ESPB leads to less pain and less need for pain medication after surgery. The ESPB involves an injection of a local anesthetic, ropivacaine, into your child's back muscles to help block pain signals.

Key Dates

Start date
Jun 6, 2025
Status verified
Apr 2026
Primary completion
Jan 26, 2027
Completion
Jan 26, 2027

Study Design

Enrollment
42 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ESPB with Ropivacaine + standard postoperative pain protocol
    Erector spinae plan block (ESPB) with Ropivacaine and standard postoperative pain protocol
  • No Intervention: No ESPB + standard postoperative pain protocol
    No erector spinae plane block (ESPB) or type of injection and standard posteropative pain protocol

Primary Outcome Measure

Compare Oral Morphine Equivalents and Benzodiazepine Doses used in the first 72 hours after surgery among patients who have a ESPB with standard postoperative pain protocols versus those with standard protocols alone. [ Time Frame: Change from Baseline to 72 hours after surgery. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia94158
Tripta Rughwani
[email protected]
415-353-4701
Stephanie Chu
[email protected]
415-353-1454
Ishaan Swarup, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California San Francisco· San Francisco, CA

Related Studies